R. Gray

发表

Bayesian Models for Gene Expression With DNA Microarray Data

J. Ibrahim, Ming-Hui Chen, R. Gray, 2002 .

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

R. Gray, B. Freidlin, E. Korn, 2008, Clinical Cancer Research.

Hazard Rate Regression Using Ordinary Nonparametric Regression Smoothers

R. Gray, 1996 .

Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis

Robert Gray, R. Gray, 1992 .

Tests for Variation over Groups in Survival Data

R. Gray, 1995 .

Annual hazard rates of recurrence for breast cancer after primary therapy.

R. Gray, D. Tormey, T. Saphner, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189.

J F Simpson, R. Gray, N. Robert, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Ingrid A Mayer, 2015, The New England journal of medicine.

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.

C K Osborne, R. Gray, C. Osborne, 1989, The New England journal of medicine.

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

R. Gray, C. Osborne, N. Robert, 1995, Journal of the National Cancer Institute.

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.

R. Gray, C. Osborne, D. Tormey, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.

H Volk, R. Gray, J. Bennett, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.

R. Gray, D. Tormey, J. Arseneau, 1985, Annals of internal medicine.

Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.

R. Gray, Bruce E. Johnson, S. Dahlberg, 2008, Journal of Clinical Oncology.

Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.

Stephen W Lagakos, R. Gray, S. Lagakos, 2010, Biostatistics.

Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.

W. Wolberg, R. Gray, D. Tormey, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2×2 Contingency Tables

Cyrus R. Mehta, Nitin R. Patel, Robert Gray, 1985 .

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer

R. Gray, C. Isaacs, J. Mandelblatt, 2019, JNCI cancer spectrum.

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.

R. Gray, D. Tormey, H. Falkson, 1996, Journal of the National Cancer Institute.

Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group

J. Manola, R. Gray, M. Atkins, 2006, Clinical Cancer Research.

Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).

W. McGuire, R. Gray, C. Osborne, 1992, Journal of the National Cancer Institute. Monographs.

Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.

R. Gray, E. Perez, T. Whelan, 2014, Journal of Clinical Oncology.

Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.

R. Gray, S. Agarwala, M. Wong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial

R. Gray, G. Sledge, D. Cella, 2021, Cancer.

Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer.

R. Gray, D. Tormey, J. Arseneau, 1986, NCI monographs : a publication of the National Cancer Institute.

A general inefficacy interim monitoring rule for randomized clinical trials

R. Gray, B. Freidlin, E. Korn, 2010, Clinical trials.

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival

B. F. Cole, R. Gray, R. Gelber, 1996, The Lancet.

The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom.

R. Gray, D. Kerr, H. Earl, 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.

R. Gray, N. Robert, W. Wood, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

R. Gray, J. Bergh, T. Powles, 2013 .

Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer

R. Gray, S. Goldberg, R. Preti, 2001, Bone Marrow Transplantation.

Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma.

R. Gray, F. Hong, B. Kahl, 2013, Blood.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

S. Luoh, R. Gray, K. Flaherty, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Robert Gray, R. Gray, J. Schiller, 2006, The New England journal of medicine.

Meaningful Subset Analyses Contribute to Optimal Patient Care

R. Gray, S. Ramalingam, J. Schiller, 2008 .

Pragmatic approaches to address expansion cohort design

R. Gray, S. Dahlberg, 2018, Cancer.

Randomized clinical trial design for assessing noninferiority when superiority is expected.

R. Gray, B. Freidlin, E. Korn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concerns about chemotherapy are legitimate

R. Gray, J. Northover, 1996, BMJ.

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

George W. Sledge, David L. Page, Robert Gray, 2013, Journal of the National Cancer Institute.

Reply to C. Shah et al.

R. Gray, E. Perez, A. Recht, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.

R. Gray, E. Perez, G. Sledge, 2012 .

S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.

R. Gray, G. Sledge, S. Shak, 2011 .

Efficacy of radiotherapy for ovarian ablation

R. Gray, S. Martino, N. Robert, 2004, Cancer.

ECOG 4599 phase III trial of carboplatin and paclitaxel ±bevacizumab: Subset analysis of survival by gender.

R. Gray, Douglas B. Johnson, J. Schiller, 2006, Journal of Clinical Oncology.

Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.

R. Gray, T. Whelan, G. Sledge, 2021, JAMA oncology.

Tumor in ﬁ ltrating lymphocyte strati ﬁ cation of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2021 .

Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC).

M. Ostland, R. Gray, J. Schiller, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps.

R. Gray, J. Sparano, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.

R. Gray, M. Knuiman, D. Tormey, 1986, NCI monographs : a publication of the National Cancer Institute.

Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis

R. Gray, K. Flaherty, L. Rubinstein, 2016 .

Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials

R. Gray, Haesook T. Kim, 2012, Clinical trials.

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

R. Gray, J. Schiller, A. Dowlati, 2008, Clinical Cancer Research.

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

Carlos L. Arteaga, R. Gray, K. Flaherty, 2022, JCO precision oncology.

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2–negative breast cancer: A trajectory analysis of adverse events

R. Gray, D. Cella, I. Gareen, 2021, Cancer.

Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).

R. Gray, J. Schiller, A. Dowlati, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

R. Gray, E. Perez, D. Miles, 2010 .

Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.

R. Gray, D. Tormey, K. Gilchrist, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

R. Gray, M. Piccart, F. Cardoso, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

R. Gray, D. Cella, Shaji K. Kumar, 2022, Blood Cancer Journal.

GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.

R. Gray, S. Martino, G. Sledge, 2009 .

Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.

R. Gray, A. Recht, B. Fowble, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

R. Gray, S. Adams, R. Kurzrock, 2021, Clinical Cancer Research.

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Robert Gray, Jason P. Fine, R. Gray, 1999 .

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer

R. Gray, T. Rohan, J. Sparano, 2017, npj Breast Cancer.

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

R. Gray, J. Sparano, N. Davidson, 2013, Cancer.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Molin Wang, George W. Sledge, Antonio C. Wolff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Heikki Joensuu, Carsten Denkert, Damien Drubay, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

R. Gray, K. Flaherty, L. Rubinstein, 2021, Clinical Cancer Research.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

S. Luoh, R. Gray, K. Flaherty, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2018, The New England journal of medicine.

Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.

J. Olson, M. Ellis, R. Gray, 2020, Journal of the National Cancer Institute.

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Sally Hunsberger, R. Gray, R. Gelber, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership

Robert Gray, Carlos L. Arteaga, Lisa M. McShane, 2016 .

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.

R. Gray, K. Flaherty, L. Rubinstein, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

R. Gray, K. Flaherty, L. Rubinstein, 2020, Clinical Cancer Research.

Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group

G. T. Budd, R. Gray, S. Martino, 2011, Medical Oncology.

Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy.

R. Gray, B. Fowble, D. Tormey, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial.

R. Gray, K. Flaherty, L. Rubinstein, 2016 .

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

Robert Gray, Kathy Miller, R. Gray, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients.

R. Gray, B. Fowble, D. Tormey, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B080: Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) precision medicine trial

R. Gray, A. Iafrate, J. Sklar, 2018 .

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

Adjuvant therapy for very young women with breast cancer: need for tailored treatments.

R. Gray, R. Gelber, J. Bryant, 2001, Journal of the National Cancer Institute. Monographs.

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

David J. Sims, R. Gray, A. Iafrate, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

R. Gray, J. Schiller, I. Dimery, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

R. Gray, S. Ramalingam, J. Schiller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.

R. Gray, M. Vangel, R. Komaki, 2003, Lung cancer.

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.

R. Gray, C. Osborne, W. Gradishar, 2003, The New England journal of medicine.

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

R. Gray, M. Citron, N. Robert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

R. Gray, K. Flaherty, L. Rubinstein, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

R. Gray, K. Flaherty, L. Rubinstein, 2022, JCO precision oncology.

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.

Carlos L. Arteaga, R. Gray, K. Flaherty, 2020, JAMA oncology.

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.

R. Gray, K. Flaherty, L. Rubinstein, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

R. Gray, K. Flaherty, P. Hammerman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

David J. Sims, R. Gray, A. Iafrate, 2020, Journal of the National Cancer Institute.

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

R. Gray, J. Schiller, A. Dowlati, 2005 .

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

R. Gray, G. Tang, S. Shak, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Virginia G Kaklamani, Soonmyung Paik, Matthew P Goetz, 2019, The New England journal of medicine.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

J. Olson, M. Ellis, R. Gray, 2020, JAMA oncology.

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

J. Olson, R. Gray, H. Gómez, 2018, Journal of Clinical Oncology.

Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.

J. Olson, R. Gray, W. McCaskill-Stevens, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

R. Gray, E. Perez, S. Martino, 2012, Breast Cancer Research and Treatment.

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

R. Gray, G. Sledge, J. Sparano, 2012, Breast Cancer Research and Treatment.

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations

R. Gray, M. Dowsett, J. Deasy, 2019, JNCI cancer spectrum.

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

R. Gray, S. Adams, R. Kurzrock, 2020 .

Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.

R. Gray, Jinbo Chen, A. DeMichele, 2009, Cancer research.

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers

R. Gray, S. Loi, B. Leyland-Jones, 2017, JCO precision oncology.

Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

R. Gray, J. Schiller, David H. Johnson, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

R. Gray, T. Shanafelt, D. Cella, 2020 .

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

R. Gray, J. Cuzick, M. Dowsett, 2020 .

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Silvana, R. Gray, E. Perez, 2011 .

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011 .

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

J. Olson, R. Gray, H. Gómez, 2019, Journal of Clinical Oncology.

Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

R. Gray, W. McCaskill-Stevens, T. Whelan, 2019, General Session Abstracts.

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.

R. Gray, D. Tormey, T. Saphner, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.

R. Gray, H. Lazarus, R. Weiner, 1994, Bone marrow transplantation.

An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology

R. Gray, B. Freidlin, E. Korn, 2013, Clinical trials.

HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197

R. Gray, G. Sledge, S. Shak, 2008 .

Noninferiority trials with nonadherence to the assigned randomized treatment

R. Gray, B. Freidlin, E. Korn, 2019, Clinical trials.

Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

R. Gray, S. Shak, S. Badve, 2007 .

Locoregional F ailure 1 0 Y ears A fter M astectomy and A djuvant C hemotherapy W ith o r W ithout T amoxifen Without I rradiation: E xperience o f t he E astern Cooperative O ncology G roup

R. Gray, A. Recht, B. Fowble, 1999 .

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial

R. Gray, J. Wolter, P. Carbone, 1990, Cancer.

Evaluating Antiangiogenesis Agents in the Clinic

R. Gray, J. Sparano, R. Comis, 2004, Clinical Cancer Research.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer

D. Berry, E. Feuer, R. Gray, 2018, Journal of the National Cancer Institute.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

R. Gray, E. Perez, S. Martino, 2009, Clinical Cancer Research.

Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.

Molin Wang, Robert Gray, R. Gray, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2018, npj Breast Cancer.

Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

R. Gray, T. Rebbeck, P. Gimotty, 2010, Breast Cancer Research.

Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial.

R. Gray, T. Whelan, G. Sledge, 2022, JAMA oncology.

Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy

R. Gray, T. Whelan, G. Sledge, 2021, Cancer.

E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2017, npj Breast Cancer.

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.

R. Gray, K. Flaherty, L. Rubinstein, 2019, Journal of Clinical Oncology.

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.

Daniel J. Sargent, R. Gray, D. Sargent, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

Daniel L. Koller, R. Gray, Lang Li, 2014, British Journal of Cancer.

High DNA content and prognosis in lymph node positive breast cancer. A case control study by the university of Leiden and ECOG

Robert Gray, Wilma E. Mesker, Kennedy W. Gilchrist, 2004, Breast Cancer Research and Treatment.

Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.

S. Luoh, R. Gray, K. Flaherty, 2018 .

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

R. Gray, C. Sotiriou, S. Loi, 2022, NPJ breast cancer.

Weighted analyses for cohort sampling designs

R. Gray, 2009, Lifetime data analysis.

Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.

R. Gray, D. Tormey, K. Gilchrist, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P5-14-04: Effects of dose-dense chemotherapy on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

R. Gray, R. Peto, L. Norton, 2017 .

On Tests for Group Variation With a Small to Moderate Number of Groups

R. Gray, 1998, Lifetime data analysis.

Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

R. Gray, C. Sotiriou, S. Loi, 2019 .

Methodology for case-control studies with prevalent cases

R. Gray, C. Begg, 1987 .

An Audit Strategy for Progression‐Free Survival

Suman Bhattacharya, Lori E Dodd, Boris Freidlin, 2011, Biometrics.

Proposal for the use of progression-free survival in unblinded randomized trials.

Boris Freidlin, Robert Gray, Edward L Korn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

R. Gray, E. Perez, A. Recht, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

Carlos L. Arteaga, R. Gray, K. Flaherty, 2023, JCO precision oncology.

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Carlos L. Arteaga, R. Gray, K. Flaherty, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

R. Gray, E. Perez, Lang Li, 2013, Clinical Cancer Research.

Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

R. Gray, D. Sargent, D. Wickerham, 2011, Clinical Cancer Research.

When bad things happen to good studies.

J. Manola, R. Gray, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Marker Sequential Test (MaST) design

Boris Freidlin, Robert Gray, Edward L Korn, 2014, Clinical trials.

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials

R. Gray, D. Sargent, D. Wickerham, 2011, Clinical trials.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies

R. Gray, S. Shak, F. Baehner, 2018, Breast Cancer Research and Treatment.

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials

R. Gray, D. Sargent, D. Wickerham, 2010, Clinical trials.

Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

R. Gray, K. Flaherty, L. Harris, 2018 .

A kernel method for incorporating information on disease progression in the analysis of survival

Robert Gray, R. Gray, 1994 .

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group

Robert Gray, Donna Marinucci, David M Dilts, 2008, Clinical Cancer Research.

The NCI-MATCH trial: lessons for precision oncology

Carlos L. Arteaga, David J. Sims, R. Gray, 2023, Nature Medicine.

Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.

R. Gray, D. Tormey, S. Taylor, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.

J. Manola, R. Gray, K. Jensen, 2014 .

Phase III clinical trials that integrate treatment and biomarker evaluation.

Boris Freidlin, Robert Gray, Edward L Korn, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Method for Analyzing Disease-Specific Mortality with Missing Cause of Death Information

R. Gray, Ping K. Ruan, 2006, Lifetime data analysis.

Abstract OT2-1-06: E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

R. Gray, J. Sparano, A. Tevaarwerk, 2015 .

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

R. Gray, K. Flaherty, L. Harris, 2019, Clinical Trials.

Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

R. Gray, S. Martino, G. Sledge, 2013 .

Abstract OT2-01-04: E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group

R. Gray, J. Sparano, A. Tevaarwerk, 2016 .

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial

R. Gray, H. Gómez, S. Paik, 2019, General Session Abstracts.

Are HER2-positive breast cancer and BRCA mutation-associated breast cancer mutually exclusive diseases? Evidence from the Mayo Clinic Arizona Cohort.

R. Gray, B. Pockaj, A. Dueck, 2010 .

Marker Sequential Test (MaST) design

R. Gray, B. Freidlin, E. Korn, 2014, Clinical trials.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

J. Olson, M. Ellis, R. Gray, 2015, The New England journal of medicine.

When bad things happen to good studies.

J. Manola, R. Gray, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On regression analysis with incomplete covariate data

R. Gray, 1998 .

Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

J. Olson, R. Gray, T. Whelan, 2023, Cancer Research.